IFPMA Priorities At WHA: Election, Antibiotics, Cancer, Pandemics 17/05/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment The new head of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has hit the ground running in Geneva, and is weighing in on a variety of policy issues, this week providing a list of priorities for the research-based pharma industry at the upcoming annual World Health Assembly.
World Health Assembly Topic: Pandemic Flu Financing, Virus Sharing, Extension 17/05/2017 by Catherine Saez, Intellectual Property Watch Leave a Comment There are many who see the World Health Organization mechanism to prepare and face the next influenza pandemic and insure availability of treatments as a success. However, some questions remain.
IP-Watch Guide To 2017 World Health Assembly: Election, Budget, Antibiotics, Cancer, R&D And More 16/05/2017 by Catherine Saez, Intellectual Property Watch 1 Comment In a few days, the 70th World Health Assembly will open its doors in Geneva with a marathon agenda, and over 4,000 registered delegates. The election of a new director general, the approval of the budget for the next biennium (2018/2019) are set to capture the attention of member states. However, many other subjects require their consideration, such as a resolution on cancer treatment costs, research and development for epidemic diseases, for new antibiotics, for medicines affecting primarily poor populations, access to medicines, and the influenza pandemic preparedness framework.
Longest, Biggest World Health Assembly Ever Set To Open With Election, Budget Topping Agenda 12/05/2017 by Catherine Saez, Intellectual Property Watch 4 Comments The 70th World Health Assembly opening in a few days is the WHA of superlatives, according to a World Health Organization’s official. It is the longest assembly ever, with nine days of meeting, the largest number delegates, of agenda items, and of documents. It is also when the new WHO new director general will be elected, and when the WHO next budget is expected to be approved.
WHO, Stakeholders Take ‘First Step’ On Fair Pricing For Medicines 12/05/2017 by Catherine Saez and William New, Intellectual Property Watch 3 Comments The World Health Organization has concluded a major one-day forum on fair pricing of medicines, bringing a wide range of stakeholders together in Amsterdam and coming up with several possible actions for the way ahead. Key points of discussion included a definition of fair pricing, moving away from value-based pricing, delinkage of price from research and development costs, and greater transparency, according to participants.
WHO Touts Its Past Work On Improving Access To Medicines 11/05/2017 by Intellectual Property Watch Leave a Comment The World Health Organization today published an item entitled, Access to medicines: making market forces serve the poor, a chapter from its report ‘Ten years in public health 2007-2017’ of outgoing WHO Director General Margaret Chan.
Shortage Of Affordable Insulin: Should WHO Extend Prequalification To Biosimilars? 10/05/2017 by Tatum Anderson for Intellectual Property Watch 2 Comments The WHO last week announced plans to explore options for prequalifying insulin, a process that already assesses the quality, safety and efficacy of medicinal products, such as tuberculosis and malaria drugs. The WHO is considering whether to extend the prequalification process to manufacturers creating me-too versions of insulins, more commonly known as biosimilars.
US, EU Diverge On Medical Diagnostic Patents 10/05/2017 by Kim Treanor for Intellectual Property Watch 1 Comment A recent article in the journal Nature Biotechnology finds that since a key United States Supreme Court decision, the European Union and United States have diverged in their patent filings for medical diagnostics.
MSF Warns Of Threats To Public Health In Asian Trade Agreement IP Proposals 09/05/2017 by Intellectual Property Watch 1 Comment The 18th round of the Regional Comprehensive Economic Partnership (RCEP) trade agreement negotiations is taking place this week in Manila, Philippines. Health activists warn that Japan and South Korea are pushing for measures that go beyond international trade rules on intellectual property, including extending patent terms and data exclusivity in countries such as India, a primary source of cheaper generic medicines.
The True Believer: An Interview With New IFPMA Director General Thomas Cueni 08/05/2017 by Catherine Saez and William New, Intellectual Property Watch 2 Comments The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has long been at the centre of global public health policy in Geneva, representing industry from around the world. Now at a critical moment of change in the policymaking machinery, a new leader, Thomas Cueni of Switzerland, has taken over. Intellectual Property Watch recently sat down with him to discuss his views and vision going forward, and discovered his intellectual pragmatism and diverse experience which promise to open an ambitious new era for the association and global health policy.
